Opinion|Videos|November 10, 2023
Achieving Superior Treatment Durability and Outcomes In Neovascular AMD and DME
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Advertisement
0:00 Introduction
0:56 Need for durable treatments in nAMD and DME
4:29 Mechanism of faricimab
7:14 Highlights from clinical trials for faricimab
10:33 Post hoc analyses of faricimab clinical trials
16:24 Factors affecting retreatment decision
19:28 Durability data for faricimab
23:22 Experience with faricimab
29:06 Choosing between faricimab and high-dose aflibercept
32:51 Final remarks
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Related to this article
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.
At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.
Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.
Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.
HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.
Advertisement
Advertisement